Sarah Raifman, PhD, MSc

Sarah is a Project Director at ANSIRH, leading a phase IV clinical trial evaluating the feasibility, acceptability, and effectiveness of mail-order pharmacy dispensing of mifepristone for medication abortion in the US. She is also part of the Nepal Turnaway Study, where she investigates whether those denied legal abortion care in Nepal have worsened physical health consequences, as well as the Drug-Alcohol and Pregnancy Policy Study (D-APPS), where she investigates the potential effects of US state-level policies targeting alcohol and drug use during pregnancy on birth outcomes. She received a BA in Development Studies from Brown University, MSc in Global Health from the Harvard School of Public Health, and PhD in Epidemiology & Translational Science from UCSF.